Results 11 to 20 of about 14,745,234 (347)
Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients [PDF]
Frontiers in MedicineBackgroundThe EXXELERATE study revealed poorer clinical outcomes in patients treated with adalimumab (ADL) and baseline rheumatoid factor (RF) above 203 IU/mL.Chamaida Plasencia-Rodríguez, Chamaida Plasencia-Rodríguez, Ana Martínez-Feito, Ana Martínez-Feito, Marta Novella-Navarro, Marta Novella-Navarro, Rebeca Pérez De Diego, Rebeca Pérez De Diego, Rebeca Pérez De Diego, Gema Bonilla, Gema Bonilla, Johanna Elin Gehin, Alejandro Villalba-Yllán, Laura Nuño, Dora Pascual-Salcedo, Pilar Nozal, Pilar Nozal, Mariana Díaz Almirón, Alejandro Balsa, Alejandro Balsa +19 moredoaj +2 more sourcesFirst-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis [PDF]
Journal of Comparative Effectiveness ResearchAim: To compare characteristics of patients with anticitrullinated protein antibody-positive (ACPA+) and
rheumatoid factor-positive (RF+) rheumatoid arthritis (RA) who initiated abatacept or a tumor necrosis
factor inhibitor (TNFi) as a first-line ...Gordon Lam, Hanke Zheng, Andrew Klink, Vardhaman Patel, Emily Bland, Laetitia N’Dri, Parisa Asgarisabet, Keith Wittstock, Cherrishe Brown-Bickerstaff, Mark Chaballa, Vadim Khaychuk, Bruce Feinberg +11 moredoaj +2 more sourcesRheumatoid Factor
Citation: 'rheumatoid factor' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13652 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms. Requests Tiwari V, Jandu JS, Bergman MJ.europepmc +2 more sourcesTreatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
New England Journal of Medicine, 1997 L. Moreland, Scott W. Baumgartner, M. Schiff, E. Tindall, R. Fleischmann, A. Weaver, R. Ettlinger, S. Cohen, W. Koopman, K. Mohler, M. Widmer, C. Blosch +11 moresemanticscholar +3 more sourcesA trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
New England Journal of Medicine, 1999 M. Weinblatt, J. Kremer, A. Bankhurst, K. Bulpitt, R. Fleischmann, Robert I. Fox, C. G. Jackson, M. Lange, D. Burge +8 moresemanticscholar +3 more sourcesGenome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis [PDF]
, 2013 Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumatoid arthritis (RA). It is unknown why some RA patients fail to respond adequately to anti-TNF therapy, which limits the development of clinical biomarkers ...A Parker, AI Catrina, AL Price, Alison Motsinger-Reif, AM van Gestel, Ann W. Morgan, Anne Barton, Anthony G. Wilson, Atsuo Taniguchi, B Devlin, Barbara E. Stranger, BE Stranger, BJ Scallon, C Liu, C Miceli-Richard, Chikashi Terao, Corinne Miceli, Cornelia F. Allaart, D Aeberli, D Plant, D Plant, DL Scott, Dorothee Diogo, EA Stahl, EA Stahl, EJ Toonen, Eli A. Stahl, Elizabeth W. Karlson, FM Batliwalla, Fumihiko Matsuda, Gert Jan Wolbink, GM Cooper, Gosia Trynka, H Canhao, Helena Canhao, Henk-Jan Guchelaar, Hisashi Yamanaka, IB McInnes, Irene E. van der Horst-Bruinsma, J Agnholt, J Cui, J Ernst, J Marchini, J. Bart A. Crusius, Jing Cui, Johan Askling, John D. Isaacs, João Eurico Fonseca, Katsunori Ikari, Kimme L. Hyrich, Koichiro Ohmura, L Klareskog, L Padyukov, Larry W. Moreland, LD Ward, Leonid Padyukov, Lindsey A. Criswell, M Martin, Manik Kuchroo, Marieke E. Doorenspleet, Marieke Herenius, Marieke J. H. Coenen, Mart van de Laar, Maša Umiċeviċ Mirkov, Michael E. Weinblatt, MJ Coenen, ML Prevoo, MM Soliman, Namrata Gupta, Nancy A. Shadick, Niek de Vries, O Stegle, Paul-Peter Tak, Peter K. Gregersen, Philip L. De Jager, PI de Bakker, Piet L. C. M. van Riel, PL De Jager, R Prajapati, Rene E. M. Toes, RM Plenge, Robert M. Plenge, Robert P. Kimberly, S Gudbrandsdottir, S Purcell, S. Louis Bridges, SA Gauthier, Saedis Saevarsdottir, Sara Wedrén, SG Tangye, Shigeki Momohara, Soumya Raychaudhuri, Tom W. J. Huizinga, Towfique Raj, Tsuneyo Mimori, Xavier Mariette, Y Okada, Yukinori Okada +97 morecore +17 more sourcesEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Annals of the Rheumatic Diseases, 2022 Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field.J. Smolen, Robert B. M. Landewé, S. Bergstra, A. Kerschbaumer, A. Sepriano, D. Aletaha, R. Caporali, C. Edwards, K. Hyrich, J. Pope, Savia de Souza, T. Stamm, T. Takeuchi, P. Verschueren, K. Winthrop, A. Balsa, J. Bathon, M. Buch, G. Burmester, F. Buttgereit, M. Cardiel, K. Chatzidionysiou, C. Codreanu, M. Cutolo, A. D. den Broeder, K. El Aoufy, A. Finckh, J. Fonseca, J. Gottenberg, E. Haavardsholm, A. Iagnocco, K. Lauper, Zhanguo Li, I. McInnes, E. Mysler, P. Nash, G. Poór, G. Ristić, F. Rivellese, A. Rubbert-Roth, H. Schulze-Koops, N. Stoilov, Anja Strangfeld, A. H. M. van der Helm-van Mil, E. van Duuren, T. V. Vliet Vlieland, R. Westhovens, D. M. van der Heijde +47 moresemanticscholar +1 more source
